Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 3/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6936625 | 0.92 | CDC7 (0.54) | GCGRMAPK14MAPT | |
| SCHEMBL6936911 | 0.92 | CDC7 (0.54) | GCGRMAPK14MAPT | |
| SCHEMBL6936901 | 0.87 | GCGR (0.67) | GCGRMAPK14 | |
| SCHEMBL6936494 | 0.86 | MAPK14 (0.44) | MAPK14MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL6936510 | 0.86 | GCGR (0.55) | GCGRMAPK14 | |
| SCHEMBL7457594 | 0.86 | MAPK14 (0.50) | GCGRMAPK14 | |
| SCHEMBL6932091 | 0.84 | MAPK14 (0.56) | GCGRMAPK14ALDH1A1MAPT | |
| SCHEMBL6934768 | 0.84 | MAPK14 (0.55) | GCGRMAPK14 | |
| SCHEMBL27505558 | 0.84 | GCGR (0.47) | GCGRMAPK14 | |
| SCHEMBL6937695 | 0.79 | MAPK14 (0.49) | GCGRMAPK14MEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073704-A1 | Substituted pyridone compounds and methods of use | AMGEN INC. | 2003-04-17 | — | — | US | claimed |
| US-6420385-B1 | INFLAMMATORY, PAIN AND DIABETES DISEASES, | AMGEN INC. | 2002-07-16 | — | — | US | claimed |
| US-6649604-B2 | Analgesics; antidiabetic agents; antiinflamamtory agents | AMGEN INC. | 2003-11-18 | — | — | US | disclosed |
| US-20030073704-A1 | Substituted pyridone compounds and methods of use | AMGEN INC. | 2003-04-17 | — | — | US | disclosed |
| US-6420385-B1 | INFLAMMATORY, PAIN AND DIABETES DISEASES, | AMGEN INC. | 2002-07-16 | — | — | US | disclosed |
| US-6096753-A | Substituted pyrimidinone and pyridone compounds and methods of use | AMGEN INC. (US) | 2000-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073704-A1 | Substituted pyridone compounds and methods of use | IL6, IL1B, IL1A | GCGR 2219/4885MAPK14 1169/4885MEN1 2461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.